Business
INVO to Report Second Quarter 2023 Financial Results on Monday, August 14, 2023
Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET SARASOTA, Fla., Aug. 9, 2023 /PRNewswire/ -- INVO
About this update from Invo Fertility, Inc.
[{"type":"text","content":"Financial results to be released after market close; Conference call to be conducted at 4:30 pm ET\nSARASOTA, Fla., Aug. 9, 2023 /PRNewswire/ -- INVO Bioscience, Inc. (NASDAQ: INVO), a healthcare services fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the intravaginal culture (\"IVC\") procedure it enables, will report financial results for its second quarter 2023, for the period ended June 30, 2023, after the market close on Monday, August 14, 2023. The Company has scheduled a conference call that same day, Monday, August 14, 2023, at 4:30 pm ET, to review the results.\n\n \n \n \n \n \n \n\n \nSecond Quarter 2023 Conference Call Details\nDate and Time: Monday, August 14, 2023, at 4:30 pm ET\nCall-in Information: Interested parties can access the conference call by dialing 833-756-0861 or 412-317-5751.\nLive Webcast Information: Interested parties can access the conference call via a live webcast, which is available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ or https://app.webinar.net/y0l43MO6o9Z.\nReplay: A teleconference replay of the call will be available through August 21, 2023, at 877-344-7529 or 412-317-0088, replay access code #8863258. A webcast replay will be available in the Investor Relations section of the Company's website at https://www.invobioscience.com/investors/ for 90 days. \nAbout INVO Bioscience\nWe are a healthcare services fertility company dedicated to expanding the assisted reproductive technology (\"ART\") marketplace by making fertility care accessible and inclusive to people around the world. Our commercialization strategy is focused on the opening of dedicated \"INVO Centers\" offering the INVOcell® and IVC procedure (with three centers in North America now operational), the acquisition of US-based, profitable in vitro fertilization (\"IVF\") clinics and the sale and distribution of our technology solution into existing fertility clinics. Our proprietary technology, INVOcell®, is a revolutionary medical device that allows fertilization and early embryo development to take place in vivo within the woman's body. This treatment solution is the world's first intravaginal culture technique for the incubation of oocytes and sperm during fertilization and early embryo developme...